Cardialysis is a leading specialized Clinical Research Organization (CRO) with an exclusive focus on cardiology. Cardialysis provides the full range of clinical research services necessary for the fast-track, high-quality development of medical devices, pharmaceutical products and combinations in phase II and phase III, registry and post-marketing trials and investigator initiated studies. All processes are in compliance with Good Clinical Practice (GCP), guidelines of the European Medicines Agency (EMA), the Food and Drug Administration (FDA), the International Conference on Harmonization (ICH) and ISO standards.
Cardialysis is headquartered in Rotterdam, the Netherlands and has global reach through its monitoring network in Western and Eastern European countries and via a network of preferred CRO partners for outside European countries. Through its network of over 1400 clinical sites monitored by local CRAs specialized in cardiology, Cardialysis has access to a large part of the cardiological clinical trial population in the world.
The company has a track record of over 350 clinical development trials including several landmark trials that have contributed to the major advances in cardiology over the last 34 years and to the approval of drugs and devices currently used in every-day practice around the world.
Mission and Vision
It is our mission to serve the interests of our clients and our global network of collaborating cardiology professionals, and most importantly to pursue improvements in the care of patients, by offering and continuously improving our unique state-of-the-art full-service infrastructure for the design and conduct of the smartest trials with the world’s most promising innovations.
Cardialysis was incepted in 1983 by cardiologists from the Thorax center of the Erasmus Medical Center in Rotterdam, the Netherlands; the medical center that still plays a prominent role in the expanding international faculty that surrounds Cardialysis today. From a small Holter data analysis unit in the early eighties, Cardialysis has developed into an internationally recognized independent clinical research organization, collaborating with major scientific, medical device and pharmaceutical partners from around the world. Nowadays, Cardialysis has a long, diversified track record and is one of the leading specialized global organizations for drug and medical device development in the field of cardiology.